We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.
Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Efficacy Investigated for Electrochemiluminescence Immunoassay

By Labmedica International staff writers
Posted on 20 Mar 2019
Print article
Image: The cobas e 602 integrates immunoassay and clinical chemistry testing on a single platform (Photo courtesy of Roche).
Image: The cobas e 602 integrates immunoassay and clinical chemistry testing on a single platform (Photo courtesy of Roche).
Syphilis caused by Treponema pallidum is a chronic bacterial infection. T. pallidum cannot be cultured in vitro, and new molecular tests for syphilis are unlikely to replace serology in the short term because they are fairly expensive and require sophisticated equipment.

Antibody detection by non-treponemal and treponemal tests is still regarded as the mainstay for diagnosing syphilis and monitoring treatments. Treponemal tests detect antibodies for treponemal antigens. There are many treponemal tests, such as the fluorescent treponemal antibody absorption (FTA-ABS) test, IgG immunoblot test for T. pallidum, enzyme immunoassay (EIA), and chemiluminescence immunoassay (CLIA).

Scientists at the Sungkyunkwan University School of Medicine (Seoul, Republic of Korea) collected samples from 4,771 subjects included in a study. They performed rapid plasma reagin (RPR), electrochemiluminescence immunoassay (ECLIA), and Treponema pallidum particle agglutination (TPPA) according to these three algorithms. The fluorescent treponemal antibody absorbed (FTA-ABS) test was additionally applied for discordant cases between the RPR and ECLIA results. The FTA-ABS results and the consensus of three algorithms were considered a gold standard.

The non-treponemal test, a quantitative RPR, the Mediace rapid plasma reagin test was performed on the Roche P800. The treponemal test, the Roche Diagnostics’ Elecsys Syphilis assay, which is an automated ECLIA, was performed using the Roche e602 platform and interpreted according to 1.0 cutoff index (COI). The automated ECLIA simultaneously detects anti-treponemal IgG and IgM antibodies using recombinant TP antigens such as TpN15, TpN17, and TpN47. The FTA-ABS IgG and IgM were also tested in the specimens showing discordance among the RPR, ECLIA, and TPPA results for confirmation.

The team reported that a total of 208 subjects were diagnosed with syphilis. The traditional algorithm had a sensitivity of 25.96%, specificity of 100%, and accuracy of 96.8%. Both the reverse and European Centre for Disease Prevention and Control (ECDC) algorithms showed the same diagnostic performance, sensitivity of 95.2%, specificity of 99.96%, and accuracy of 99.75%. The agreements between the traditional algorithm and the other algorithms were 96.9% with a kappa value of 0.415.

The authors concluded that their study indicated that the reverse or ECDC algorithm using the ECLIA as a first-line screening test and the TPPA as a second treponemal test could detect more cases of missed serodiagnosis by the traditional algorithm. The reverse algorithm could contribute to the appropriate serodiagnosis of syphilis with superior diagnostic performance. The study was published in the March 2019 issue of the International Journal of Infectious Diseases.

Related Links:
Sungkyunkwan University School of Medicine


Print article

Channels

Copyright © 2000-2019 Globetech Media. All rights reserved.